Search: 

Which vaccines to invest in and when
– GAVI’s strategic approach

GAVI has been developing a comprehensive vaccine investment strategy in 2008 to determine which vaccines it will offer to countries in the future, ensuring the best use of resources and maximum immunisation impact.

The strategy is needed because the landscape of vaccine development has changed dramatically since GAVI's creation in 2000. Then there were relatively few new vaccines of relevance to the developing world.

Now there are several new vaccines in development and many other possibilities on the horizon, stimulated by

In developing the vaccine investment strategy GAVI is evaluating vaccines that will become available over the next five years in comparison with each other, taking into account their relative impact, importance to countries, product availability and the availability of resources.

A list of 18 priority vaccines has been drawn up by WHO. GAVI’s strategy is determining in which order, or if at all, these vaccines will be offered to countries.

Method

The development of the investment strategy is being carried out in four phases during 2008.

  • Diagnosis: GAVI has gathered relevant information from Alliance partners and stakeholders to profile each disease/vaccine under consideration and has considered the types of associated activities that could be funded to ensure successful vaccine introduction. (February - March)
  • Consultations: Seven in-country consultations were carried out, along with online, video and phone consultations to solicit input from key stakeholders. The full consultation report of country input will be available on this website. (March - April)
  • Synthesis and vaccine evaluations: Based on the outcomes of the diagnostic research and analysis and the consultations, each disease/vaccine has been examined individually and in comparison. From this, a range of scenarios, or vaccine portfolio themes associated with packages of multiple vaccines over different timeframes, has been identified. The Joint Executive Committees has prioritised the themes, and an independent review committee has validated the appropriateness of the specific vaccine packages options against the chosen themes. (April – May)
  • Strategy development and investment requirements: The recommended vaccine investment theme will be presented to the GAVI Alliance Board (June), identifying the package of associated vaccines and activities that GAVI would support, as well as an indicative investment envelope along with long-term income projections. Following a decision by the Board, an implementation plan will be prepared considering the specific financial implications (and corresponding fundraising strategy) as well as the associated activities and timeframe for investments.(July – September)
The process described above includes inputs from multiple stakeholders, the project steering committee, the GAVI Working Group and the GAVI Joint Executive Committees. Extensive in-country consultations and consultations with Alliance partners, product development partnerships and other key players in the field of global immunisation were also conducted.

A Board paper on the Vaccine Investment Strategy was presented to the GAVI Board on 25 June 2008. Please see the downloadable background documents below: